Dr. Gomella on the FDA Approval of Apalutamide for Nonmetastatic CRPC
February 20th 2018
Leonard Gomella, MD, professor, chair, Department of Oncology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the FDA approval of apalutamide (Erleada) for the treatment of patients with nonmetastatic castration-resistant prostate cancer.